000			01823cam a2200349 i 4500
999			_c2147 _d2147
001			4926565
005			20201006142007.0
008			950822s1996 enka b 001 0 eng
020			_a0471957135 (alk. paper)
040			_aDLC _erda _cDLC _dDLC _beng
082	0	0	_a615.7882 _220 _bC.N.A
100	1		_aCutler, Neal R. _98812 _eauthor.
245	1	0	_aAnxiolytic compounds : _bperspectives in drug development / _cNeal R. Cutler and John J. Sramek, Neil M. Kurtz.
264		1	_aChichester ; _aNew York : _bJohn Wiley, _c[1996]
264		4	_ccopyright 1996
300			_aviii, 163 pages : _billustrations ; _c24 cm
336			_atext _btxt _2rdacontent
337			_aunmediated _bn _2rdamedia
338			_avolume _bnc _2rdacarrier
500			_aErratum slip inserted.
504			_aIncludes bibliographical references and index.
505	0		_aPreface Abbreviations used in the Text 1 Perspectives On the Worldwide Market for Anxiolytics 1 2 A Retrospective Analysis of the Drug Development of Currently Approved Anxiolytics 31 3 Methodological Issues in Drug Development 61 4 Novel Anxiolytics 109 5 Role of the 'Bridging' Study in Facilitating Development of Potential Anxiolytics 139 6 Perspectives on International Regulatory Requirements 153 Concluding Remarks 157 Index
650		0	_aTranquilizing drugs _xDevelopment.
700	1		_aSramek, John J. _98814 _eauthor.
700	1		_aKurtz, Neil M. _98815 _eauthor.
856	4	2	_3Publisher description _uhttp://www.loc.gov/catdir/description/wiley031/95039622.html
856	4		_3Table of Contents _uhttp://www.loc.gov/catdir/toc/onix02/95039622.html
906			_a7 _bcbc _corignew _d1 _eocip _f19 _gy-gencatlg
942			_2ddc _cBK